MARKET WIREChartMill • 5d ago
Top U.S. Gainers and Losers for Oct. 27, 2026 SessionOct. 27, 2026 U.S. top movers: BRAI led gainers at 73.58%, while DVLT led losers at -49.02%, ranked by percentage change.
Why IMNN Stock advanced +0.35% Today — RQD Quant Desk Flash
$0.83 +0.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.83
Imunon Inc. (IMNN) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $4.7M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.83 (-0.13%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMNN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY IMNN SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (31% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$1.08-5.6% Next Q
50
Q2 (-2Q)Grade D$1.02+21.6% Next Q
47
Q3 (-1Q)Grade D$1.24-33.1% Next Q
45
CurrentGrade D-$0.83-7% Hist 90D α
42
Trajectory: C- (50) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMNN Turnaround Squeeze
While IMNN currently carries a cautious 42/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.31) and Max Pain ($0.87) forces dealer call-delta covering toward $4.83.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMNN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMNN Stock advanced +0.35% Today — RQD Quant Desk Flash
Imunon Inc. (IMNN) advanced +0.35% to $0.83, trading at 2% of its 52-week range ($0.81 – $4.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.81 – $4.6) with RSI-14 at 35.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.83 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IMNN Headlines & Catalysts
MARKET WIREChartMill • 5d ago
Premarket Movers: Gainers and Losers Ahead of Today's US OpenPremarket movers ahead of the US open: BRAI, OPENZ, NEXR, XXII and AUROW among top gainers, while DVLT, SPRC, ARTV and ACTU lead declines.
MARKET WIREBenzinga • 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday SessionGainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release, Q3 earnings
MARKET WIREBenzinga • 5d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionGainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock moved
MARKET WIREYahoo • 11d ago
IMUNON Announces Strategic Sale of ThermoDox®Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON's Commitment to Its Core
MARKET WIREBenzinga • 11d ago
IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And RoyaltiesAgreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma TrialSale Reinforces IMUNON's Commitment to Its
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMNN)
- ✓Walkthrough of IMNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.67%🛡️ HOLDING TREND SUPPORT
2026-10-30O $0.84H $1.00L $0.83C $0.83VOL 131.6K
RES: $1.42SUP: $0.72SMA50: $1.31SMA200: $2.24
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMNN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMNN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMNN)
Health Care Rank #598 of 1016
⚔️ TRAW vs IMNN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMNN vs. TRAW, AZTR, APUS, XBIO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Imunon Inc. (IMNN) ranks #598 by composite RQD confidence (42/100, grade D-) and #952 by equity capitalization ($4.7M). Within this direct 5-issuer industry benchmark cohort, IMNN leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. XBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with IMNN at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMNN
ACTIVE
Imunon Inc. | D- | 42/100 | — | — | -35.0% | +0.35% | $4.7M | Benchmark Subject |
| TRAW Traws Pharma Inc. | D- | 38/100 | — | — | -35.0% | -16.34% | $4.6M | /traw-vs-imnn → |
| AZTR Azitra Inc | D- | 41/100 | — | — | -35.0% | -16.31% | $4.6M | /aztr-vs-imnn → |
| APUS Apimeds Pharmaceuticals US Inc. | D- | 43/100 | — | — | -6.2% | +4.56% | $5.0M | /apus-vs-imnn → |
| XBIO Xenetic Biosciences Inc. | D | 47/100 | — | — | -30.3% | +0.95% | $5.0M | /xbio-vs-imnn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000749647In its most recent audited fiscal period (FY2025, filed 2025-12-31), Imunon Inc. (IMNN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $14.5M, operating cash flow of -$13.9M, and free cash flow of -$14.2M (+24.9% YoY). On the balance sheet, IMNN closed FY2025 with $12.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $14.5M | -$13.9M | -$14.2M | $12.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$18.6M | -$18.9M | -$18.9M | $9.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$19.5M | -$19.0M | -$19.0M | — | — |
3. IMNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Imunon Inc. (NASDAQ: IMNN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.83 (+0.35% 1D, market cap $4.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IMNN ranks #598 in composite RQD confidence.
How does IMNN compare to TRAW and AZTR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMNN carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TRAW (Traws Pharma Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $4.6M) and AZTR (Azitra Inc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $4.6M). Among the 5-stock peer group, IMNN leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMNN?
Per IMNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000749647), Imunon Inc. generated $0 in revenue, $14.5M in net income, and -$14.2M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMNN trading relative to its 50-day, 200-day, and 52-week technical levels?
IMNN last traded at $0.83 (+0.35% on volume of 211,777 shares), positioning the stock -36.64% below its 50-day simple moving average ($1.31) and -62.95% below its 200-day simple moving average ($2.24). Across its 52-week range of $0.81 to $4.60, IMNN sits at the 0.5% percentile with a 14-day RSI of 35.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.93).
IMNN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMNN stock moving today?
Why IMNN Stock advanced +0.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.